Rybrevant

Rybrevant (amivantamab-vmjw) is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring: EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy, OR EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test, in combination with chemotherapy or lazertinib. <a id="